Myelofibrosis involving lymph node: a novel cytogenetic abnormality in a mimicker of mesenchymal neoplasm by Hu, Youjun et al.
CASE REPORT
Myelofibrosis involving lymph node: a novel cytogenetic
abnormality in a mimicker of mesenchymal neoplasm
Youjun Hu & Ann-Leslie Zaslav &
Neetu Radhakrishnan & Marc Golightly &
Colette Pameijer
Received: 13 May 2009 /Accepted: 10 June 2009 /Published online: 30 June 2009
# Springer-Verlag 2009
Abstract A case of primary myelofibrosis involving lymph
node and with a novel cytogenetic abnormality [del (18)
(p11.2-3)] is reported. The abnormalities are identical
among specimens from the lymph node, peripheral blood,
and bone marrow that were analyzed years apart. Addition-
ally, we show that the infiltrate by dysplastic megakaryo-
cytes in the lymph node morphologically mimics a
metastatic mesenchymal neoplasm, even when the clinical
history myelofibrosis was known.
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Introduction
Primary myelofibrosis (PMF) is a rare chronic myeloprolifer-
ative disorder that usually involves the bone marrow with
proliferation of megakaryocytes and granulocytic elements
and has a variable degree of marrow fibrosis (1). When the
marrow is fibrotic, there is usually myeloid metaplasia or
extramedullary hematopoiesis that involves most commonly
the spleen and liver. Other organs occasionally may be
involved as well, such as lymph node, breast, skin, urinary
bladder, etc.(2). The exact molecular mechanism of myelo-
fibrosis is not clear. No specific recurrent cytogenetic
abnormalities have been described. Diagnosis of extramedul-
lary hematopoiesis involving lymph nodes or other organs is
usually straightforward, given the appropriate clinical setting.
Here, we report a case of myelofibrosis in which the lymph
node is infiltrated with dysplastic megakaryocytes along with
fibrosis. The cytogenetic abnormality in the lymph node was
the same as that identified in the marrow 4 years prior. The
morphological changes raised the possible differential
diagnosis of metastatic mesenchymal neoplasm, even though
the clinical history of myelofibrosis was known.
Clinical course
The patient is a 71-year-old female who was diagnosed with
primary myelofibrosis 16 years ago when she presented with
anemia and splenomegaly. Four years ago, the patient became
transfusion-dependent. The marrow was fibrotic with clusters
of dysplastic megakaryocytes and largely diminished normal
hematopoietic elements. Her transfusion requirements de-
creased once she was started on thalidomide and prednisone
with anagrelide and hydroxyurea for thrombocytosis. After
approximately 1 year, she again became transfusion-
dependent and continued on only hydroxyurea for thrombo-
cytosis. Last year, the hydroxyurea was discontinued after she
receivedsplenic radiationforsymptomaticsplenomegaly.The
patient developed secondary hemochromatosis and was
placed on iron chelation therapy. Ten months ago, her spleen
was again irradiated for symptomatic splenomegaly. Subse-
quently,thepatientpresentedwithcongestiveheartfailuredue
to severe pulmonary hypertension of unclear etiology.
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nary infiltrates, or valvular or ischemic heart diseases was
negative. She was started on sildenafil for pulmonary
hypertension and hypoxia. The patient has been on erythro-
poietin supplementation for 2 years. Her physical exam was
remarkable for a hard, mobile right axillary node 2×1 cm in
size. There was moderate to massive splenomegaly and
hepatomegaly. No focal lesions were found on an ultrasound
of the liver. The complete blood cell count showed mild
leukopenia, anemia, and a platelet count of 360×10
3/μl.
Circulating blasts were 2% (stable for the last 6 months).
Test for JAK2 mutation was negative. Biopsy of the enlarged
axillary lymph node was performed.
Materials and methods
Histologic and immunohistochemical studies
The specimen was processed following routine histologic
procedures including routine H&E stain and immunohisto-
chemical stains. The antibodies were from Dako (antibodies
Vimentin, CD3, CD20 and CD45, Carpinteria, CA, USA)
and Invitrogen (antibodies CD61 and Cytokeratin AE1/
AE3, Carlsbad, CA, USA). The automatic immunostainer
was Bond-maX (Leica Microsystems, Australia).
Flow cytometry study
A portion of fresh tissue was sent for flow cytometry
analysis. Analysis was performed on FACScalibur 2000
from Becton Dickinson (San Jose, CA, USA). The anti-
bodies (BCL2, CD3, CD4, CD5, CD7, CD8, CD10, CD14,
CD19, CD20, CD21, CD22, CD23, CD30, CD33, CD34,
CD38, CD45, CD56, Cytokeratin, EpCAM, FMC7, Glyco-
phorin, HLA-DR, Kappa light chain, Lambda light chain)
were purchased from the same company. CD43 was from
Caltag, Carlsbad, CA, USA.
Cytogenetics study
Cytogenetic G-banded metaphase analysis and fluorescence
in situ hybridization (FISH) were performed using standard
cytogenetic techniques on bone marrow (BM), the lymph
node biopsy, and unstimulated blood (UB). Analyses were
performed four different times during the course of treatment.
ForFISH,200nucleiwerescoredperprobe.Thefollowing
probes were used: 6/25/07 (UB specimen): LSI 5q EGR1/
D5S23 (5q31,5p15.2), the LSI D7S486/CEP 7 (7q31/7p11.1-
q11.1(D7Z1)), the LSI CEP 8 (8p11.1-q11.1(D8Z2)) and the
LSI21(21q22.13-q22.2)probes;1/4/08(UBspecimen):allof
the previous probes and the LSI MLL DC BAR (11q23)
probe; 8/20/08 (lymph node specimen): 18p11.3 (D18S552)
Fig. 1 a Interphase nuclei
probed with the TelVysion CEP
18 (Aqua) centromere probe
and the 18p (yellow) probes
(Abbott Mol, Inc). Presence of
only one yellow signal indicates
loss of one 18p (11.3). The
right nucleus indicates the
presence of both 18p signals
(i.e., normal). b G-banded
karyotype demonstrating the
deleted chromosome 18p (11.2).
The arrow indicated the deleted
18p homolog
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Results including flow cytometry and cytogentetics
The lymph node specimen was received fresh, measuring
1.2×1.2×0.7 cm, and felt a bit firm grossly.
A portion of the fresh specimen was sent for cytogenetic
analysis. Cytogenetic metaphase analysis of the lymph node
was not performed due to lack of metaphase cells. FISH
analysis demonstrated a loss of the p11.3 region of
chromosome 18 using a subtelomere probe specific for
the p11.3 region of chromosome 18 (yellow dot signal,
Fig. 1a, left field). A probe for the p11.2 region of
chromosome 18 was not available. With cytogenetic
metaphase analysis of the BM specimen 4 years ago and
UB specimen from last year, chromosomal karyotyping
revealed a karyotype of 46, XX, del(18) (p11.2)[30]/46,XX
[8] (i.e., a deletion of most of the short arm of chromosome
18; Fig. 1b).
FISH demonstrated normal signal patterns for chromo-
somes 5, 7, 11, and 21 in all nuclei from UB specimens
from last year and 10 months ago.
Microscopically, the lymph node specimen showed
distorted nodal architecture by an infiltrate of bizarre, giant
cells (Figs. 2a and 3). While there was marked fibrosis, a
significant component of tumoral spindle cell proliferation
process was not seen. The giant cells showed nuclear
lobulation with irregular chromatin distribution and abun-
dant cytoplasm. Multinucleated giant cells were also seen.
Abnormal mitotic activities were present. The dysplastic
changes of the giant cells were so profound that a
mesenchymal malignancy was considered the most likely
diagnosis during our initial workup, even though the history
of myelofibrosis was known. Most of the giant cells
appeared larger than the dysplastic megakaryocytes on the
marrow core biopsy sections from 4 years prior (Fig. 2b)
Fig. 2 a Lymph node biopsy, H&E stain, ×200 magnification. b Bone
marrow core biopsy, H&E stain, ×200 magnification
Fig. 3 a Lymph node biopsy,
immunostain for vimentin, ×200
magnification. b Lymph node
biopsy, immunostain for
cytokeratin, ×200 magnification.
c Lymph node biopsy,
immunostain for CD45, ×200
magnification. d Lymph
node biopsy, immunostain
for CD61, ×200 magnification
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seen on the marrow. There were also scattered, large
mononuclear cells that were smaller than the giant cells.
These cells showed dysplastic and malignant-appearing
nuclei. Other hematopoietic elements were not obvious.
The dysplastic cells and the giant cells were negative for
vimentin and cytokeratin by immunohistochemical stain
(Fig. 3a, b). Vimentin stains the interstitial cells on the
lymph node section. Not surprisingly, the giant cells were
also negative for CD45 (Fig. 3c), CD3, and CD20 (data not
shown). Immunohistochemical stain for CD61, a marker of
megakaryocytes (Integrin beta 3, also called platelet
glycoprotein IIIa), was added and showed strong cytoplas-
mic staining in most of the giant cells (Fig. 3d). A diagnosis
of myelofibrosis involving lymph node with infiltrating
dysplastic megakaryocytes was then made as a result of the
findings. The case was later seen by an outside consultant
who concurred with the diagnosis.
Flow cytometry analysis of the node indicated less than
1% myeloid blasts based on the light scatter characteristics
and combination of CD34 and CD33 positivity (data not
shown). Additionally, there was no evidence of monoclonal
B cells, abnormal T cells, cytokeratin-positive cells, or
CD30-positive cells (data not shown).
Discussion
To our knowledge, this was the first case of PMF associated
with a deletion of part of the short arm of chromosome
18 (3) The cytogenetic and FISH studies revealed deletions
of the short arm of chromosome 18 in bone marrow,
unstimulated blood, and lymph node at various times. As
the deletion of part of the short arm of chromosome 18
detected in the karyotypes from BM and UB extended from
p11.2 to the terminus of the short arm, it represented a
much larger area of the genome than the FISH probe
covered. Therefore, the deletion in BM and UB cells was
apparently the same as the deletion of p11.3 of chromo-
some 18 detected by interphase FISH in the lymph node. To
our knowledge, deletions of chromosome 18 have not been
reported to be associated with primary myelofibrosis.
Numerical abnormalities of chromosomes 7, 8, and 9 and
structural changes of 1q, 5q, 13q, and 20q have been
reported in primary myelofibrosis (4–6). The deletion of
18p seen in this patient may reflect the loss of one or
more critical genes within the deleted region that could be
associated with the disease state in this patient. Loss of
homozygosity of chromosome 18p11.3 was reported in
breast cancer, both invasive carcinoma and in situ ductal
carcinoma (7). Amplification of the 18p11.3 band was seen
in esophageal carcinoma (8). A putative tumor suppressor
gene, DAL-1, was recently mapped to chromosome band
18p11.3 (9). Cytogenetic abnormalities of chromosome
8p11 involving fibroblast growth factor receptor 1 (FGFR1)
gene has been described in a subset of chronic myelopro-
liferative disorder to which primary marrow fibrosis
belongs to (10). FISH of 8p11 has not been performed
and may be pursued in the follow-up of the patient.
As far as the histopathologic diagnosis is concerned, it is
clear that clinical history can provide important clues that
lead to the correct diagnosis. In this case, without the
history, it would have been much harder to include the
myeloid metaplasia into the differential diagnosis. Second-
ly, both the lymph node and the bone marrow showed that
megakaryocytes can be the predominant element of
myeloid metaplasia in myelofibrosis. In addition, the
megakaryocytes outside the marrow may be very dysplastic
and have different morphological features from that in the
marrow. It is possible that the marked fibrosis may have
affected the morphology of megakaryocytes in the marrow.
Myeloid metaplasia usually shows infiltration by multiple
immature hematopoietic elements such as nucleated eryth-
rocytes, early myeloid cells, and megakaryocytes. A correct
diagnosis is often straightforward. However, if the process
constitutes only or predominantly dysplastic megakaryo-
cytes as in this case, it could be a diagnostic challenge.
Immunohistochemistry was invaluable in the diagnosis of
this case. The availabilityofspecificantibodies helped torule
out certain differential diagnoses. CD61 antibody, which is a
routinely used marker for megakaryocytes, helped to confirm
the diagnosis.
In this patient, the finding of a small number of
myeloblasts in the lymph node specimen by flow analysis
was a hint for a possible myeloid process and led to
appropriate workup. On the other hand, the number of
myeloblasts was not high enough to suggest a blastic
crisis.
Last, while there was no histological evidence, it was
conceivable that the patient's pulmonary problems were
related to circulating megakaryocytes plugging the capillaries
in the lungs. This has been documented in the literature (11),
especially when there were no other identifiable causes
found in the pulmonary workup.
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